SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950142-22-003160
Filing Date
2022-11-14
Accepted
2022-11-14 06:51:39
Documents
17
Period of Report
2022-11-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh220304751_8k.htm   iXBRL 8-K 33210
2 EXHIBIT 99.1 eh220304751_ex9901.htm EX-99.1 13487
3 EXHIBIT 99.2 eh220304751_ex9902.htm EX-99.2 88483
4 GRAPHIC logo.jpg GRAPHIC 11450
5 GRAPHIC nrx.jpg GRAPHIC 3213
  Complete submission text file 0000950142-22-003160.txt   393897

Data Files

Seq Description Document Type Size
6 XBRL DEFINITION FILE nrxp-20221112_def.xml EX-101.DEF 26608
7 XBRL LABEL FILE nrxp-20221112_lab.xml EX-101.LAB 36687
8 XBRL SCHEMA FILE nrxp-20221112.xsd EX-101.SCH 3958
9 XBRL PRESENTATION FILE nrxp-20221112_pre.xml EX-101.PRE 25232
11 EXTRACTED XBRL INSTANCE DOCUMENT eh220304751_8k_htm.xml XML 5562
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 221379983
SIC: 2834 Pharmaceutical Preparations